Pasong Kawayan I, Philippines

De La Salle Health Sciences Institute

dlshsi.edu.ph
Pasong Kawayan I, Philippines

The De La Salle Health science Institute is the medical school of De La Salle University, a Roman Catholic, Lasallian research university in the Philippines. It is an institution involved in health care education and research located along the Mangubat Avenue in Dasmariñas City, Cavite. It was established in 1987 when the Hermano San Miguel Febres Cordero Medical Educational Foundation, Inc. acquired ownership of the Emilio Aguinaldo College of Medicine. In 1994 it was renamed alongside with the Medical Center as the De La Salle-Health science Campus. In 2007, in order to signal the institution's drive to pursue its mission, the institution officially became the De La Salle Health science Institute and is a member of De La Salle Philippines. Currently, the Institute is composed of 3 major units which are the Institutional Colleges , the De La Salle University Medical Center, and the Angelo King Medical Research Center. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Jain V.K.,Glaxosmithkline | Rivera L.,Hospital Maternidad Nuestra Senora Of La Altagracia | Zaman K.,Center for Child and Adolescent Health | Espos Jr. R.A.,De La Salle Health Sciences Institute | And 19 more authors.
New England Journal of Medicine | Year: 2013

BACKGROUND: Commonly used trivalent vaccines contain one influenza B virus lineage and may be ineffective against viruses of the other B lineage. We evaluated the efficacy of a candidate inactivated quadrivalent influenza vaccine (QIV) containing both B lineages. METHODS: In this multinational, phase 3, observer-blinded study, we randomly assigned children 3 to 8 years of age, in a 1:1 ratio, to receive the QIV or a hepatitis A vaccine (control). The primary end point was influenza A or B confirmed by real-time polymerase chain reaction (rt-PCR). Secondary end points were rt-PCR-confirmed, moderate-to-severe influenza and rt-PCR-positive, culture-confirmed influenza. The vaccine efficacy and the effect of vaccination on daily activities and utilization of health care resources were assessed in the total vaccinated cohort (2584 children in each group) and the per-protocol cohort (2379 children in the QIV group and 2398 in the control group). RESULTS: In the total vaccinated cohort, 62 children in the QIV group (2.40%) and 148 in the control group (5.73%) had rt-PCR-confirmed influenza, representing a QIV efficacy of 59.3% (95% confidence interval [CI], 45.2 to 69.7), with efficacy against culturecon-firmed influenza of 59.1% (97.5% CI, 41.2 to 71.5). For moderate-to-severe rt-PCR-confirmed influenza, the attack rate was 0.62% (16 cases) in the QIV group and 2.36% (61 cases) in the control group, representing a QIV efficacy of 74.2% (97.5% CI, 51.5 to 86.2). In the per-protocol cohort, the QIV efficacy was 55.4% (95% CI, 39.1 to 67.3), and the efficacy against culture-confirmed influenza 55.9% (97.5% CI, 35.4 to 69.9); the efficacy among children with moderate-to-severe influenza was 73.1% (97.5% CI, 47.1 to 86.3). The QIV was associated with reduced risks of a body temperature above 39°C and lower respiratory tract illness, as compared with the control vaccine, in the per-protocol cohort (relative risk, 0.29 [95% CI, 0.16 to 0.56] and 0.20 [95% CI, 0.04 to 0.92], respectively). The QIV was immunogenic against all four strains. Serious adverse events occurred in 36 children in the QIV group (1.4%) and in 24 children in the control group (0.9%). CONCLUSIONS: The QIV was efficacious in preventing influenza in children. Copyright © 2013 Massachusetts Medical Society.


PubMed | University of Seoul, De La Salle Health Sciences Institute, The Armed Forces Capital Hospital, Kyung Hee University and Seoul National University
Type: | Journal: Pain practice : the official journal of World Institute of Pain | Year: 2016

The purpose of this study was to adapt the painDETECT Questionnaire (PD-Q) into a Korean version (KPD-Q) and validate it.A single-center prospective observational study was performed. During the first phase of the study, linguistic adaptation was carried out to develop the KPD-Q. During the second phase of the study, feasibility, internal consistency, discriminant validity, and concurrent validity were assessed for psychometric validation of the KPD-Q.A total of 232 patients participated. Among them, 82 patients (35%) were classified in the neuropathic pain (NeP) group, 80 (34%) in the nociceptive pain group, and 70 (30%) in the mixed pain group. Regarding the reliability of the KPD-Q, internal consistency for the whole scale was 0.804, as evaluated by Cronbachs alpha. Pearsons correlation between the Leeds Assessment of Neuropathic Symptoms and Signs scale and the KPD-Q scores was positive and statistically significant (r = 0.74, P < 0.001). Similar to the result obtained by the original developers, a value of 19 points suggested a clear diagnosis of the presence of an NeP component with 95.4% sensitivity, 73.8% specificity, and 0.737 Youden index. We used 13 (as opposed to 12, as suggested previously) as an alternative cutoff value, which showed a sensitivity of 95.4%, specificity of 73.8%, and the Youden index of 0.691.The KPD-Q showed good psychometric and discriminant features for assessing the neuropathic component in chronic pain patients. We hope that this newly validated KPD-Q will be recognized in Korea as a credible tool for detection of NeP and thus may be used in further international clinical research.


Phillips M.,Menssana Research, Inc. | Phillips M.,New York Medical College | Basa-Dalay V.,De La Salle Health Sciences Institute | Blais J.,Menssana Research, Inc. | And 9 more authors.
Tuberculosis | Year: 2012

Rationale: Volatile organic compounds (VOCs) in breath provide biomarkers of tuberculosis (TB) because Mycobacterium tuberculosis manufactures VOC metabolites that are detectable in the breath of infected patients. Objectives: We evaluated breath VOC biomarkers in subjects with active pulmonary TB, using an internet-linked rapid point-of-care breath test. Methods: 279 subjects were studied at four centers in three countries, Philippines, UK, and India, and data was analyzed from 251 (130 active pulmonary TB, 121 controls). A point-of-care system collected and concentrated breath and air VOCs, and analyzed them with automated thermal desorption, gas chromatography, and surface acoustic wave detection. A breath test was completed in 6 min. Chromatograms were converted to a series of Kovats Index (KI) windows, and biomarkers of active pulmonary TB were identified by Monte Carlo analysis of KI window alveolar gradients (abundance in breath minus abundance in room air). Measurements and main results: Multiple Monte Carlo simulations identified eight KI windows as biomarkers with better than random performance. Four KI windows corresponded with KI values of VOCs previously identified as biomarkers of pulmonary TB and metabolic products of M. tuberculosis, principally derivatives of naphthalene, benzene and alkanes. A multivariate predictive algorithm identified active pulmonary TB with 80% accuracy (area under curve of receiver operating characteristic curve), sensitivity = 71.2%, and specificity = 72%. Accuracy increased to 84% in age-matched subgroups. In a population with 5% prevalence, the breath test would identify active pulmonary TB with 98% negative predictive value and 13% positive predictive value. Conclusions: A six-minute point-of-care breath test for volatile biomarkers accurately identified subjects with active pulmonary TB. © 2011 Elsevier Ltd. All rights reserved.


Phillips M.,Menssana Research, Inc. | Phillips M.,New York Medical College | Basa-Dalay V.,De La Salle Health Sciences Institute | Bothamley G.,NHS England | And 5 more authors.
Tuberculosis | Year: 2010

Background: Volatile organic compounds (VOCs) in breath may contain biomarkers of active pulmonary tuberculosis derived from the infectious organism (metabolites of Mycobacterium tuberculosis) and from the infected host (products of oxidative stress). Methods: We analyzed breath VOCs in 226 symptomatic high-risk patients in USA, Philippines, and UK, using gas chromatography/mass spectroscopy. Diagnosis of disease was based on sputum culture, smear microscopy, chest radiography and clinical suspicion of tuberculosis (CSTB). Chromatograms were converted to a series of 8 s overlapping time slices. Biomarkers of active pulmonary tuberculosis were identified with a Monte Carlo analysis of time-slice alveolar gradients (abundance in breath minus abundance in room air). Results: Breath VOCs contained apparent biomarkers of active pulmonary tuberculosis comprising oxidative stress products (alkanes and alkane derivatives) and volatile metabolites of M. tuberculosis (cyclohexane and benzene derivatives). Breath biomarkers identified active pulmonary tuberculosis with C-statistic (area under curve of receiver operating characteristic) = 0.85 (i.e. 85% overall accuracy, sensitivity = 84.0%, specificity = 64.7%) when sputum culture, microscopy, and chest radiography were either all positive or all negative. Employing a single criterion of disease, C-statistic = 0.76 (smear microscopy), 0.68 (sputum culture), 0.66 (chest radiography) and 0.65 (CSTB). Conclusion: A breath test identified apparent biomarkers of active pulmonary tuberculosis with 85% accuracy in symptomatic high-risk subjects. © 2010 Elsevier Ltd. All rights reserved.

Loading De La Salle Health Sciences Institute collaborators
Loading De La Salle Health Sciences Institute collaborators